Satellos Bioscience Inc. (MSLE) vs Pluri Inc. (PLUR)
A side-by-side comparison of Satellos Bioscience Inc. and Pluri Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MSLE
Satellos Bioscience Inc.
$8.05HealthcareDelayed quote: Oct 6, 2026, 1:37 PM EDT
PLUR
Pluri Inc.
$0.98HealthcareDelayed quote: Oct 6, 2026, 1:51 PM EDT
Total return — MSLE vs PLUR
growth of $100 · dividends reinvested · last 1yMSLE +13.7% (+13.7%/yr)PLUR -66.8% (-66.8%/yr)MSLE compounded faster over this window
MSLE PLUR
MSLE vs PLUR: by the numbers
- •PLUR is the larger company ($11M vs $10M market cap).
- •Both run net losses; MSLE's is the smaller (0.00% vs -2406.00% net margin).
Metrics side by side
Valuation
| Metric | MSLE | PLUR |
|---|---|---|
| P/S ratio | N/A | 10.43 |
| P/B ratio | 0.17 | N/A |
Profitability
| Metric | MSLE | PLUR |
|---|---|---|
| Gross margin | 0.00% | 44.59% |
| Operating margin | 0.00% | -2455.91% |
| Net margin | 0.00% | -2406.00% |
| ROE | -57.34% | N/A |
| ROIC | -59.35% | -127.37% |
Growth (annualized)
| Metric | MSLE | PLUR |
|---|---|---|
| Total return CAGR (5Y) | N/A | -44.78% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.